Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;64(14):2351-2353.
doi: 10.1080/10428194.2023.2262641. Epub 2023 Dec 25.

Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab

Robert Stuver  1 , Santosha A Vardhana  1 , Akshay Bedmutha  2 , Karmela Kim Chan  3 , Rosna Mirtcheva-Trocheva  2 , Anton Nosov  2 , Heiko Schöder  2 , Alison Moskowitz  1
Affiliations

Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab

Robert Stuver et al. Leuk Lymphoma. 2023 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trend of lactate dehydrogenase (LDh) and white blood cells (WBC) over time. Time 0 represents the timepoint at which pembrolizumab was initiated. additional timepoints are indicated via green arrows. mTX: methotrexate; peT: positron emission tomography; pR: partial response.
Figure 2.
Figure 2.
Representative maximum intensity projection (mip) images over time. at left is imaging three months prior to initiation of methotrexate. in center is imaging four months after initiation of methotrexate. at right is imaging two week after cessation of methotrexate.
See this image and copyright information in PMC

References

    1. Chen R, Zinzani PL, Fanale MA, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125–2132. - PMC - PubMed
    1. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294. - PMC - PubMed
    1. Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;41(17_suppl):LBA4–LBA4.
    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med. 2012;366(26):2443–2454. - PMC - PubMed
    1. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. - PMC - PubMed

MeSH terms

LinkOut - more resources